Pramana
ABOUT US
We are driven to continue to deliver Novel Best in Class Therapeutics to the clinic for the benefit of millions of patients.
Our proprietary platform activates an immune response supported by a new mechanism of action
Life-changing biotech
Our IP portfolio is robust and covers a vast library of wholly owned small molecules, with multiple issued patents. We have the molecular equity and experience to address large unmet medical needs in Metabolic Disorders including Diabetes, Obesity and NASH.
UNMET NEEDS
GPCR Centric
We are a GPCR centric Biopharmaceutical Company advancing a broad pipeline of biologic drug candidates. Our library of Novel potent GPCR agonists was discovered and optimized in-house. Our IP portfolio is robust and covers a broad genus of small molecules, with multiple issued patents. We have the molecular equity and experience to address large unmet medical needs in Immuno- Metabolic Disorders including Diabetes, Obesity and NASH.
Accelerated Innovation
We leverage our deep scientific expertise in GPCR’s through discovery and drug development to enable accelerated innovation. At Pramana, our team is continually exploring new pathways to provide best in class candidates to the clinic. We are passionate drug hunters with a formidable track record of success. Our combined expertise and development strategies has enabled pioneering research and scientific breakthroughs.
Painting a better picture future
Pramana